Gorham--Stout disease (GSD) is a rare mono- or polyostotic condition characterized by the idiopathic intraosseous proliferation of angiomatous structures, resulting in progressive destruction and resorption of bone (Rauh and Gross [@CIT0027], Boyer et al. [@CIT0003], Dellinger et al. [@CIT0006]). Gorham and Stout ([@CIT0010]) specified the condition concluding that "the progressive osteolysis is always associated with an angiomatosis of blood and sometimes of lymphatic vessels, which seemingly are responsible for it."

Today, around 300 cases of GSD have been described. Clinical manifestations depend on the affected site as well as on evolving sequelae, like bone deformity, spontaneous fractures, pericardial effusion, chyloperitoneum, or chylothorax due to leaks in the lymphatic vessels network or thoracic duct invasion (Patrick [@CIT0025], Tie et al. [@CIT0029], Ludwig et al. [@CIT0020]). The diagnosis of GSD can be difficult and laboratory findings are usually normal (Liu et al. [@CIT0018]). Local radiographs may initially demonstrate unspecific patchy radiolucencies (Adams et al. [@CIT0001], Ramaroli et al. [@CIT0026]), while progressive bone osteolysis can be observed later on (Kuriyama et al. [@CIT0016]; Dellinger et al. [@CIT0006]). The final diagnosis is based on histopathological examination of a biopsy specimen of the affected bones (Dellinger et al. [@CIT0006], Zanelli et al. [@CIT0034]).

There have been isolated reports in the literature describing cases where an osteolysis stopped progressing after several to many years (Boyer et al. [@CIT0003]). Treatment options include systemic treatment with bisphosphonates, sirolimus and interferon alpha-2b (IFNα-2b), radiation, and local surgery but no gold standard has yet emerged (Hammer et al. [@CIT0012], Heyd et al. [@CIT0014], Li et al. [@CIT0017], Mo et al. [@CIT0022], Ramaroli et al. [@CIT0026]).

We evaluated the long-term disease course of patients with GSD focusing on clinical disease features, treatment including bisphosphonates, and sequelae, as well as patients' QoL using a combination of standardized scoring systems (Tunn et al. [@CIT0030]).

Patients and methods {#s0002}
====================

7 consecutive patients (5 males) who were diagnosed with GSD in our department between 1995 and 2018 were included in this study. All patients were symptomatic and/or had documented disease progression. Anonymized pertinent data were obtained from patients' records. Patients' quality of life at last follow-up was determined using a combination of standardized scoring systems, as proposed by Tunn et al. ([@CIT0030]): Musculoskeletal Tumor Society Score (MSTS), Toronto Extremity Salvage Score (TESS), and Reintegration to Normal Living (RNL) Index.

The median age at diagnosis was 14 years (5--42) and the median follow-up amounted to 7 years (1--22). The median time from first symptoms to final diagnosis was 27 months (3--60). All patients complained of local pain without history of previous trauma, combined with local swelling in 3 cases, restricted range of movement in 1, case and weight loss in another case. 4 patients had a polyostotic and 3 patients a monoostotic disease ([Table 1](#t0001){ref-type="table"}). The diagnosis was histopathologically confirmed in all patients. Biopsies showed dilated thin-walled lymphatic and vascular vessels within rarefied lamellar bone ([Figure 1](#F0001){ref-type="fig"}).

###### 

Dilated thin-walled lymphatic and vascular vessels within rarefied lamellar bone.
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###### 

Clinical data of 7 patients with GSD

  Patient   Sex      Age diagnosed   Follow-up   Initial symptoms             Involved bones
  --------- -------- --------------- ----------- ---------------------------- -----------------------------------------------------------------------------
  1         Male     5y7m            7y3m        Pain, swelling               Skull, thoracic and lumbar vertebrae, ribs, RL pelvis, RL femur, RL humerus
  2         Female   29y1m           9y3m        Pain                         R ilium
  3         Male     21y2m           2y3m        Pain, swelling               RL femur, L pelvis, R humerus, thoracic and lumbar vertebrae
  4         Male     13y8m           21y10m      Pain                         Thoracic and lumbar vertebrae, sternum, RL pelvis, R humerus
  5         Female   11y7m           8m          Pain, swelling               L tibia
  6         Male     42y7m           6y10m       Pain, shoulder impingement   L scapula
  7         Male     12y4m           4y7m        Pain, weight loss            Cervical vertebrae

Results {#s0003}
=======

Local surgical treatment was required in 4 patients ([Table 2](#t0002){ref-type="table"}). 1 patient underwent plate fixation after a femoral fracture ([Figure 2](#F0002){ref-type="fig"}), while another patient required occipitocervical fusion due to a progressive atlantoaxial instability ([Figure 3](#F0003){ref-type="fig"}). A stabilizing spinal instrumentation (T6--L4) was necessary in a third patient due to progressive kyphosis. The same patient required further surgical treatment 4 years later due to progressive osteolysis of T11 and L5 leading to cerebrospinal fluid leaks. Another revision surgery was necessary 5 years later following a rod fracture due to material fatigue. The remaining patient suffered from recurrent erysipelas in his left leg, which was severely deformed from the disease ([Figure 4](#F0004){ref-type="fig"}). During an erysipelas bout he developed a life-threatening sepsis, which rendered a knee disarticulation necessary.

###### 

Patient no 1, 11-year-old boy with pathologic left distal femoral fracture with wide, dense metaphyseal bands corresponding to continuous 5-year bisphosphonate therapy (a); fracture consolidation 6 weeks postoperatively (b).
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###### 

Patient no 7, 13-year-old boy with progressive atlantoaxial instability with multiple GSD lesions in C1--C7 (a); 6 weeks after occipitocervical fusion (b).
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###### 

Patient no 5, 12-year-old girl with severely deformed left lower extremity (a) with proliferations of angiomatous structures within bone, muscle, and subcutaneous tissue (b).
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###### 

Clinical data of 7 patients with GSD

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Patient   A    B        C      Medication                                                        D                                                                                                                                                              Chylothorax
  --------- ---- -------- ------ ----------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------
  1         3m   1m       12m    08/11---today: zoledronic acid 2 mg every 4 weeks until 03/18,\   Plate osteosynthesis due to pathologic distal femoral fracture L (5y5m)                                                                                        R 4y after GSD diagnosis
                                 since 03/18: every 6 weeks\                                                                                                                                                                                                      
                                 02/10---today: cholecalciferol 1--2 x 1000 IE daily\                                                                                                                                                                             
                                 02/10---today: Ca 2 x 500 mg for 10d after zoledronic acid IV\                                                                                                                                                                   
                                 03/17---07/17 sirolimus 0.5 mg x 2 daily\                                                                                                                                                                                        
                                 --\> discontinued due to recurrent aphthous ulcerations\                                                                                                                                                                         
                                 07/15---09/17 propranolol 1 mg per kg of body weight\                                                                                                                                                                            
                                 --\> discontinued due to bradycardia                                                                                                                                                                                             

  2         2y   18m      20m    12/10---06/11 zoledronic acid 4 mg every 4 weeks\                 --                                                                                                                                                             --
                                 --\> discontinued due to incompliance                                                                                                                                                                                            

  3         5y   --       --     Due to a severe nephropathy, bisphosphonate treatment\            L knee disarticulation due to recurrent erysipelas and sepsis (0m)                                                                                             --
                                 is currently contraindicated in this patient                                                                                                                                                                                     

  4         3y   13y10m   3y6m   09/09---09/10 peginterferon alpha2b 50µg every week\              Spinal instrumentation (T6--L4) (12y7m) Augmented closure of cerebrospinal fluid leaks T11 and L5 (16y3m) Revision surgery after after rod fracture in (22y)   L 14y after GSD diagnosis **^a^**
                                 --\> discontinued due to hyperthyreosis\                                                                                                                                                                                         
                                 09/10---06/12 sirolimus 1 mg daily\                                                                                                                                                                                              
                                 --\> discontinued due to progressive chylothorax\                                                                                                                                                                                
                                 01/13---today: sirolimus 1--2 mg daily\                                                                                                                                                                                          
                                 02/10---today: zoledronic acid 4 mg every 4 weeks\                                                                                                                                                                               
                                 02/10---today: cholecalciferol 1--2 x 1000 IE daily\                                                                                                                                                                             
                                 02/10---today: Ca 2 x 500mg for 10d after zoledronic acid IV                                                                                                                                                                     

  5         3m   1m       --     02/18---today: zoledronic acid 2 mg every 4 weeks                 --                                                                                                                                                             --

  6         3y   1m       8m     01/12---today: alendronic acid 70 mg every week                   --                                                                                                                                                             --

  7         2y   1m       20m    03/14---today: zoledronic acid 4mg every 4 weeks                  Occipitocervical fusion (O--C2) due to atlantoaxial instability (8m)                                                                                           --
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

A. Time from first symptoms until diagnosis.

B. Time from diagnosis until start of medication.

C. Time of medication until stable disease.

D. Required surgery (time after initial diagnosis)

**^a^**Chylothorax surgery: pleurodesis 10/2011, pleurectomy 03/2015

2 patients developed a chylothorax 4 and 14 years after initial diagnosis, respectively ([Figure 5](#F0005){ref-type="fig"}). Surgical treatment with pleurodesis followed by pleurectomy was required in one of these patients due to progressive respiratory distress, while the other patient remains asymptomatic with a stable chylothorax for over 5 years. No patient underwent radiation treatment.

![Patient no 1, boy at age 9 year with asymptomatic right chylothorax 4 years after initial diagnosis of GSD.](IORT_A_1709716_F0005_B){#F0005}

6 patients received bisphosphonate therapy, which was contraindicated in the remaining patient due to a severe nephropathy ([Table 2](#t0002){ref-type="table"}). No adverse effects were observed under bisphosphonate treatment. Stable disease (defined as no radiographic progression of bone resorption) was achieved in 5 patients after a median of 20 months (8--42). 1 patient has been under bisphosphonate treatment for only 2 months with no radiographic follow-up as yet. 2 patients with chylothorax underwent an additional treatment with sirolimus and 1 patient an initial IFNa-2b therapy that had to be discontinued due to hyperthyreosis after 12 months of treatment ([Table 2](#t0002){ref-type="table"}).

The median MSTS at last follow-up amounted to 87% (23--97); the median TESS was 87% (43--97) while the median RNL Index amounted to 79% (39--88). Although the small number of cases in our cohort precluded the use of statistical analyses, we observed that younger patients tended to achieve better score results than patients aged 18 years and older, while male patients fared slightly better than female patients. On the other hand, we found that patients with a monoostotic and polyostotic disease had similar scores. The 2 patients who developed a chylothorax had a somewhat lower MSTS but a similar TESS and RNL Index compared with the patients without chylothorax. Good to excellent results in all 3 QoL scores were achieved in the 6 patients who received bisphosphonates whilst poor results were obtained in the patient who was not able to undergo bisphosphonate treatment ([Table 3](#t0003){ref-type="table"}).

###### 

Median values of QoL scores of 7 patients with GSD

                                MSTS   TESS   RNL index
  ----------------------------- ------ ------ -----------
  Male sex                      87     93     85
  Female sex                    83     85     77.5
  \< 18 years old               93     93     85
  \> 18 years old               77     84.5   77
  Monoostotic disease           87     87     79
  Polyostotic disease           80     87.5   80
  No bisphosphonate treatment   23     43     39
  Bisphosphonate treatment      90     90     82

MSTS -- Musculoskeletal Tumor Society Score

TESS -- Toronto Extremity Salvage Score

RNL -- Reintegration to Normal Living

Discussion {#s0004}
==========

GSD is a rare disease and severe symptoms have been described at presentation, such as bone deformities, pathologic fractures, or neurological deficits due to vertebral osteolysis (Kulenkampff et al. [@CIT0015]). However, most patients appear to initially develop unspecific symptoms such as pain, regional swelling, or a restricted range of motion (Möller et al. [@CIT0023], Patel [@CIT0024], Dellinger et al. [@CIT0006], Agyeman et al. [@CIT0002]). We have observed similar initial symptoms in our patients as well ([Table 1](#t0001){ref-type="table"}). As a result, medical consultation, imaging studies and diagnosis may be delayed, with only 2 of our patients being diagnosed within 3 months after developing complaints.

Due to disease progression and local symptoms, 6 of our 7 patients underwent bisphosphonate treatment, and 5 of them achieved radiologically stable disease, while treatment was only recently started in the remaining patient. Several case reports have demonstrated the clinical benefit from bisphosphonates (Mignogna et al. [@CIT0021], Yerganyan et al. [@CIT0033], Brance [@CIT0004], Ramaroli et al. [@CIT0026]). Hagberg et al. ([@CIT0011]) reported the first successful treatment of GSD with bisphosphonates. Following an unsuccessful radiation treatment, they initiated a bisphosphonate treatment with clodronic acid in combination with IFNa-2b in a 19-year-old male patient who suffered from progressive, polyostotic disease with a chylothorax, and achieved a "rapid improvement" of the patient's general condition. Hammer et al. ([@CIT0012]) later reported that bisphosphonate monotherapy in GSD resulted in an "immediate clinical improvement" and radiologically stable disease within two years in a 45-year-old woman.

Despite the activity and clinical benefits in GSD, various possible adverse effects of bisphosphonate treatment have been described. Besides gastrointestinal intolerance, flu-like symptoms (after intravenous application) and the development of osteonecrosis of the jaw (ONJ) have been described (Reid [@CIT0028], Wessel et al. [@CIT0032]). Despite the fact that we have administered a frequent bisphosphonate regime to the majority of patients and the average treatment duration amounted to over 4 years, none of our patients developed an ONJ or other relevant adverse effects in long-term follow-up. Informed consent to off-label usages is required as bisphosphonates are not approved by the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) for treatment of GSD (Dellinger et al. [@CIT0006]).

Another treatment option for GSD patients reported in the literature is sirolimus, an mTOR inhibitor that acts as a down-regulator of cellular proliferation and angiogenesis (García et al. [@CIT0009]). García et al. ([@CIT0009]) described a successful sirolimus treatment in a 43-year-old female patient with GSD of her left hemithorax accompanied by a left-sided chylothorax. Despite achieving remission within 4 weeks, treatment had to be discontinued due to metrorrhagia. We initiated sirolimus treatment additionally to bisphosphonate treatment in our 2 patients who developed a chylothorax. However, 1 patient developed recurrent aphthous ulcerations that required discontinuation of the treatment, while the other patient's chylothorax progressed under treatment and required surgery. In the first patient, the chylothorax remains asymptomatic and stable, so that the sirolimus treatment was not resumed.

Due to its antiangiogenic effect, treatment with IFNa-2b is also an effective treatment option in GSD. As with sirolimus, IFNa-2b is frequently used as combination therapy with bisphosphonates (Hagberg et al. [@CIT0011], Kuriyama et al. [@CIT0016], Ramaroli et al. [@CIT0026]). We initiated IFNa-2b monotherapy in our very first patient. After reports of the effect of bisphosphonate treatment in GSD, we later opted for combination therapy with bisphosphonates and IFNa-2b. Due to the development of a severe hyperthyreosis, the IFNa-2b treatment had to be discontinued. As stable disease was achieved under bisphosphonate monotherapy, the IFNa-2b treatment was not resumed.

Regarding local treatment options, several authors have reported on the effectiveness of radiotherapy in GSD (Kulenkampff et al. [@CIT0015], Dunbar et al. [@CIT0007], Rauh and Gross [@CIT0027], Heyd et al. [@CIT0014], Yerganyan et al. [@CIT0033]). Considering the relatively young age of GSD patients at diagnosis as well as the late effects of radiotherapy, including particularly the risk for secondary malignancies, we preferred to avoid radiotherapy in our patients.

Surgical treatment may be required in GSD patients both for the affected bones and for possible sequelae (Patel [@CIT0024]). In the long bones, most authors recommend resection followed by reconstruction or endoprosthetic replacement in weight-bearing bones (Turra et al. [@CIT0031], Chan et al. [@CIT0005], Ellati et al. [@CIT0008], Liu et al. [@CIT0019]).

Spinal stabilization surgery may be required in patients with spinal involvement and actual or impending neurological deficits. 2 of our patients required stabilization procedures, with one of them undergoing 2 further surgeries due to disease progression with development of cerebrospinal fluid leaks and material fatigue. Surgery might also be required in patients who develop a chylothorax---a potentially life-threatening sequela of GSD with a reported incidence of about 17% and a mortality of up to 34% (Patrick [@CIT0025], Tie et al. [@CIT0029], Ludwig et al. [@CIT0020]).

A novel finding of our study concerns the QoL of affected patients. To our knowledge, no study has previously evaluated this aspect of GSD. Good to excellent MSTS, TESS, and RNL Index scores were achieved in all patients undergoing bisphosphonate treatment. Indeed, the only patient with very poor results in our cohort was the one with a contraindication to medical treatment due to a severe nephropathy, providing further evidence to the observation that systematic treatment leads to a rapid relief of symptoms (Hagberg et al. [@CIT0011]).

Another somewhat surprising finding was that the patient-reported TESS and RNL Index were similar in patients with mono- and polyostotic disease, as well as in patients with and without sequelae ([Table 3](#t0003){ref-type="table"}). We also found that younger patients tended to have higher QoL scores compared with older patients. This fact has also been observed by other authors and could be attributed to better adaptation to the disease by younger patients who grow up with it and cope better with the subsequent impairments and disabilities (Tunn et al. [@CIT0030], Heaver et al. [@CIT0013]).

The low number of patients in our cohort is, naturally, a limitation of our study. However, among the approximately 300 cases reported, up to now, in the literature, our cohort represents one of the largest series treated at a single institution, reflecting the low incidence of GSD and the challenges of accruing large patient numbers.

In conclusion, due to its rare occurrence, diagnosis and treatment of GSD remain challenging. Off-label treatment with bisphosphonates appears to lead to a stable disease state in the majority of patients.
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